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BACKGROUND
Hepatitis B is still one of the major health problems in
the world. It is estimated that 300 million people world-
wide carry HBs antigen, and yearly 2–3 millions of peo-
ple die due to hepatitis B. Poland belongs to the coun-
tries of a middle risk of infection. The carrier rate in
Poland has been reported to be 1.6% [1]. Many studies
have shown that hepatitis B vaccination prevents both
vertical and horizontal transmissions. Therefore, obliga-
tory vaccination against hepatitis B was initiated in
Poland in 1996. The Polish Neonatal Society advises
hepatitis B vaccination just after birth in all infants,
regardless of birth weight or gestational age, but an
optimal vaccination schedule for very low birth weight
infants is still under debate [2]. The aim of the study
was the analysis of factors influencing the efficacy of
hepatitis B vaccination in very low birth weight infants.
MATERIAL AND METHODS
Subjects
Over the period of 8 years (June 1995 – June 2003) 211
newborns were recruited to the study. Inclusion criteria
were as follows: (a) birth weight £2000 g, (b) gestational
age <37 weeks, (c) age on admission <10 days, (d) neg-
ative maternal HBs antigen. Infants who had received
anti-HBs immunoglobulin were excluded.
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Summary
Background: An optimal vaccination schedule for VLBW infants is still under debate. The aim of the study was to analyze factors
influencing the efficacy of hepatitis B vaccination in VLBW infants.
Material and Methods: 211 newborns of HBsAg negative mothers (mean birth weight 1234±24g and mean gestational age
29.2±0.18 weeks) were observed. The patients who were vaccinated before their transfer to the tertiary NICU (mean age: 1 day,
range: 0–9) were enrolled into the group A (early vaccination, N=100), the others into the group B (delayed vaccination, N=111).
In the group B vaccination was postponed on average until the 53rd day of life (range: 11–179 day). According to the schedule of
vaccination two subgroups of infants were identified - receiving 3 doses (at the age of 0, 1 and 6 months, n=81) or 4 doses of vac-
cines (at the age of 0, 1, 2 and 12 months, n=105). After 2, 12 and 36 months from the beginning of vaccination the serum level of
antiHBs was measured.
Results: A positive response (≥10mIU/ml) was found after 2 months in 42 (51%) and 60 (69%) newborns (p<0.01); after 12
months in 46 (82%) and 62 (91%) newborns, and after 3 years in 25 (76%) and 37 (84%) newborns in the group A and the group
B respectively. More infants from the group A received an additional, unscheduled dose of vaccine (11% vs. 2.7%, p=0.02). Per
protocol analysis after 36 months from the beginning of vaccination reveled the significantly lower number of responders in the group
of early vaccinated babies (64% vs. 88%, p=0.04). There was a statistically significant lower response in newborns vaccinated before
the 32nd week of post conceptual age (after 2 months: 49 vs. 68%; p<0.01, after 12 months: 80 vs. 92%, and after 3 years: 74 vs.
85%). It was also found that the prevalence of Gram-negative sepsis was higher in the group B newborns that showed no response to
the vaccination. The number of responders after 36 months did not differ significantly between the groups of infants receiving 3 or 4
doses of primary vaccination (75 vs. 86%). During the follow-up no case of hepatitis B was observed.
Conclusions: Newborns’ response to hepatitis B vaccination depends on post-conceptual age. The authors suggest that the vaccination
of newborns born before the 28th week of gestational age should be delayed until the 2nd month of life. There is no evidence that a 4-
dose schedule is more effective than a 3-dose schedule in preterm infant.
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Intervention
The patients who were vaccinated before their transfer to
the tertiary NICU were enrolled into the group of early
vaccination (group A), others into the group of delayed
vaccination (group B). The newborns included into the
group A received the next vaccination according to two
schedules: from June 1995 through December 1998 four
doses of vaccine (at the age of 0, 1, 2 and 12 months) and
from January 1999 through June 2003 three doses of
vaccine (at the age of 0, 1 and 6 months). In the group B
vaccination was postponed (on average until the 53rd day
of life, range: 11–179 day). Serum HbsAg and liver
enzymes were evaluated before the first dose of vaccine.
The newborns included into the group B received vac-
cines according to two schedules: (a) at the 0, 1, 2, 12
month (from June 1995 through December 1998) or (b)
at the age of 0, 1, 6 months (from January 1999 through
June 2003). A recombinant hepatitis B vaccine was used
in all infants (Engerix B, GlaxoSmithKline Biologicals,
Belgium, 10 mg per dose or Euvax B, Aventis Pasteur, 10
mg per dose). After 2 months (after 2 doses), 12 months
(after 3 doses) and 36 months from the beginning of vac-
cination the serum level of antiHBs was measured. Blood
samples were allowed to clot and antiHBs antibody titers
were determined using commercial radioimmunoassay
kits (Abbott Laboratories). A positive response to vaccina-
tion was defined as an antiHBs level ≥10 mIU/ml.
Statistical analysis
Categorical variables were statistically analyzed using a
chi-square test or a Fischer exact test. Continuous vari-
ables were analyzed using a t-student test or a Mann-
Whitney U-test. Statistica for Windows statistical software
version 6.0PL (StatSoft, Inc.2001) was used for the analy-
ses, and p<0.05 was considered statistically significant.
RESULTS
Basic characteristic of the studied infants is presented in
Table 1. The mean birth weight (±SEM) of studied
infants equaled to 1234±24 g and the mean gestational
age (±SEM) equaled to 29.2±0.18 weeks. 74 (35%) new-
borns weighed less than 1000 g, and the birth weight of
89 (42%) newborns was between 1001–1500 g.
One hundred newborns were enrolled into the group of
early vaccination (group A) and 111 into the group of
delayed vaccination (group B). According to the schedule
of vaccination two subgroups of infants were identified –
receiving 3 doses (n=81) or 4 doses of vaccines (n=105).
Twenty-five newborns had individual schedules.
The mean follow-up time equaled to 5.3 years (range:
1.1–6.7 years). At the end of the study 149 infants were
more than 3 years old, and 62 were 1–3 years old. In all
newborns at least one antiHBs level was measured. One
hundred sixty-nine patients (80%) had the antiHBs level
measured after 2 months since the beginning of vaccina-
tion, 124 (59%) after 12 months and 77/149 (52%) after
3 years.
A positive response (≥10 mIU/ml) was found after 2
months in 42 (51%) and 60 (69%) infants (p<0.01); after
12 months in 46 (82%) and 62 (91%) children, and after 3
years in 25 (76%) and 37 (84%) children in the group A
and the group B respectively (Table 2.). More infants
from the group A received an additional, unscheduled
dose of vaccine (11% vs. 2.7%, p=0.02). Per protocol
Early hepatitis
B vaccination
(N=100)
Delayed hepatitis
B vaccination
(N=111)
p
Birth weight (g) (x±SEM)
Gestational age (wks.) (x±SEM)
Apgar score after 5 min. (Median; range)
Female
Weight at the first vaccine dose (g)(x±SEM)
Postconceptual age at the first vaccine dose (wks.) (x±SEM)
The need of mechanical ventilation
1334±35
30±0,25
6 {2–10}
50 (50%)
1371±37
30±0.4
61 (61%)
1141±31
28.6±0,2
6 {1–10}
57 (51%)
1632±39
37.7±0.68
71 (64%)
<0.01*
<0.01*
n.s.**
n.s.***
<0.01*
<0.01*
n.s.***
Table 1. Baseline characteristic of studied infants.
n.s. – non significant; * t-student test;
** Mann-Whitney U-test; *** Fischer’s exact test
Early hepatitis
B vaccination
(N=100)
Delayed hepatitis
B vaccination
(N=111)
p
(Fischer’s exact
test)
Responding to vaccine after 2 months of vaccination (n/%)
Responding to vaccine after 12 months of vaccination (n/%)
Responding to vaccine after 36 months of vaccination (n/%)
Additional dose(s) of vaccine
Responding to vaccine after 36 months of vaccination – per protocol analysis (n/%)
42/82 (51%)
46/56 (82%)
25/33 (76%)
11 (11%)
14/22 (64%)
60/87 (69%)
62/68 (91%)
37/44 (84%)
3 (2.7%)
37/42 (88%)
0.01
0.1
0.1
0.02
0.04
Table 2. Comparison of effectiveness of vaccination between the groups of early and delayed hepatitis B vaccination.
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analysis after 36 months from the beginning of vaccina-
tion reveled a significantly lower number of responders in
the group of early vaccinated babies (64% vs. 88%,
p=0.04). There was a statistically significant lower res-
ponse between children vaccinated before the 28th week of
post conceptual age and these vaccinated between the
28–32nd week of post conceptual age (Table 3.).
The number of responders after 36 months after the
beginning of vaccination did not differ significantly
between the groups of children receiving 3 or 4 doses of
vaccination (75 vs. 86%). During the follow-up no case
of hepatitis B was observed.
Additionally, risk factors influencing efficacy of vaccina-
tion in the group of infants with delayed vaccination
were analyzed. The prevalence of Gram-negative sepsis
was higher in the group B children who showed no
response to the vaccination. Birth weight, weight at vac-
cination, post conceptual age, and weight gain before
vaccination did not differ between the groups of respon-
ders and non-responders (Table 4.).
DISCUSSION
In the studied group a positive response to hepatitis B
vaccination after 2 months was noted in 60% children
and after 12 months in 87% children. In the published
studies success rate of hepatitis B vaccination was
reported as 25–66% and 52–95% respectively [3–9].
Observed differences between the studies depend on
the studied population and vaccination policies used.
In the studied population the response of early vacci-
nated babies was significantly lower compared to late
vaccinated babies. Losonsky et al. studied 148 preterm
infants vaccinated just after birth [5]. After 2 doses of
vaccine a positive response was observed only in 25%
cases. Authors observed a significantly lower response of
ELBW babies (only 11%). After 3 doses 52% of babies
who weighed less than 1000 g responded, 68% of these
who weighed between 1000–1500 g, and 84% of the
babies who weighed >1500 g. Almost all (26/27) non-
responders had birth weight <1700 g.
A comparison of the efficacy of early vaccination bet-
ween full-term and preterm newborns was presented by
Freitas de Motta et al. [10]. Three months after the 3rd
dose the seroconversion rate in preterm infants was sig-
nificantly lower than in full term infants (77% vs. 98%).
The authors conclude that the administration of hepati-
tis B vaccine shortly after birth in preterm infants with
the weight <1800 g may be inadequate.
In our population, we found a significant correlation
between maturity of the baby and its response rate. A
positive response in newborns vaccinated before the
32nd week of post conceptual age after 2 months of
beginning of vaccination occurred only in 49% cases,
after 12 months in 80%cases and after 3 years in 74%
cases. Similar observations were published by Sood et al.
[11]. A good response (antiHBs level >100 mIU/ml)
after 2 doses of vaccine was observed in 95% babies with
birth weight >2500 g, 60% infants weighing 1800–2499
g, and only 10% newborns weighing less than 1800 g.
After 3 doses the response rates were 100%, 90% and
45%, respectively.
Blondheim et al. presented results of the study compar-
ing efficacy of early vaccination between preterm and
Responders
(N=60)
Non-responders
(N=27) p
Birth weight (g) (x±SEM)
Gestational age (wks.) (x±SEM)
Apgar score after 5 min. (Median; range)
Female
Weight at the first vaccine dose (g)(x±SEM)
Postconceptual age at the first vaccine dose (wks.) (x±SEM)
Gain weight to the date of first vaccination (g/wk) (x±SEM)
The need of mechanical ventilation 
Blood products administration during 7 days after any vaccination (n/%)
Gram-negative sepsis (n/%)
1181±44
28.9±0.25
6 {1–10}
32 (52%)
1605±50
38.1±1.1
56±6.3
36 (59%)
43 (73%)
4 (6%)
1140±55
28.6±0.23
6 {1–10}
8 (30%)
1786±79
37.8±1.0
63±7.0
16 (59%)
20 (77%)
5 (19%)
n.s.*
n.s.*
n.s.**
0.06***
n.s.*
n.s.*
n.s.*
n.s.***
n.s.***
0.1***
Table 4. Risk factors influencing efficacy of vaccination in the group of infants with delayed vaccination.
n.s. – non significant; * t-student test;
** Mann-Whitney U-test; *** Fischer’s exact test
* p<0.05 for chi-square Pearson test
£28 weeks 29–32 weeks 32–36 weeks >36 weeksPostconceptual age
Responding to vaccine after 2 months of vaccination (n/%)*
Responding to vaccine after 12 months of vaccination (n/%)*
Responding to vaccine after 36 months of vaccination (n/%)
9 (40%)
13 (72%)
7 (70%)
23 (52%)
29 (86%)
16 (76%)
38 (69%)
36 (90%)
19 (86%)
32 (67%)
30 (94%)
20 (83%)
Table 3. Effectiveness of vaccination according to postconceptual age.
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full term infants [3]. After 1–2 months after the 3rd dose
of vaccine the seroconversion rate did not differ between
the studied group (88.7 vs. 93.4%). The authors con-
clude that hepatitis B vaccination is effective in most
preterm infants. However, the mean birth weight of
preterm group was 1.53 kg. In 1998, Belloni et al. pub-
lished the data of hepatitis B vaccine immunogenicity in
the cohort of 2209 neonates, including 241 preterm
babies [12]. All infants received vaccines at the age of 4
days and 1 and 6 months. There was no difference in the
seroconversion rate between the group of preterm and
full term babies 1 month after the 3rd dose of vaccine. In
the citied study, however, the authors treat less imma-
ture babies than we do.
Information on long term immunogenicity in preterm
infants is limited. Khalak et al. evaluated 16 preterm
and 17 full term babies at the age of 3 years [13]. The
ratio of a positive response was similar in both groups
(75 vs. 71%). The results of a 3-year follow-up study,
presented by Linder et al., compared two three-dose
protocols: vaccination beginning within 24 hours and
delayed until the weight of 2000 g was reached [14]. In
the group of delayed vaccination, the percentage of
infants who reached a positive antiHBs antibody level
was significantly higher (92.5 vs. 52.4%). A report of a
seven-year follow-up of vaccine response was published
by Kirmani et al. [15]. They evaluated 16 extremely
preterm babies (birth weight <1000 g, gestational age
<29 weeks). The antibody titers were significantly lower
compared to full term babies, but similar proportions of
children had protective HbsAB titers.
In our study we found a similar seroconversion rate in
children who received an early and delayed vaccination.
However, in the group of early vaccination more infants
received unscheduled doses of vaccines. Analyzing the
group of patient who received only scheduled doses; the
number of non-responders was significantly higher in
the group of early vaccinated children compared to late
vaccinated children.
Because of the lower efficacy of early vaccination, some
authors studied usefulness of early vaccination sched-
ules containing one more dose. In the study performed
by Ballesteros et al. twenty-nine preterm babies (mean
birth weight 1398 g) received doses of vaccines at birth
and the age of 1, 5 and 9 months [6]. Arora et al present
similar results [16]. In preterm infants who received the
fourth dose the proportion of infants with protective
antibody levels (12.2%) was significantly higher than the
proportion reached with only three doses.
In the present study we used 2 schedules of vaccination.
At the age of 36 months the efficacy of both schedules
was similar.
Additionally, risk factors influencing the efficacy of vacci-
nation in the group of infants with delayed vaccination
were analyzed. Birth weight, weight at vaccination, post
conceptual age, and weight gain before vaccination,
required respiratory support, blood products transfusions
and steroid treatment did not differ between the groups
of responders and non-responders. Only the prevalence
of Gram-negative sepsis was non-significantly higher in
the group of the newborns with delayed vaccination who
showed no response to the vaccination. Similar results
were presented by Blondhaim et al. [3]. Losonsky et al.
observed a correlation between the seroconversion rate
and weight gain during the first 6 months of life and the
authors suggest that babies with poor weight gain need
the evaluation of antibody titer at the age of 1 year [5].
Since 1994 the American Academy of Pediatrics recom-
mended delaying the start of hepatitis B immunization
in low-risk premature infants weighing less than 2 kg at
birth until they reach 2 kg or until 2 months of age. In
2003 this statement was reevaluated and at present the
AAP recommends to reschedule the first dose of hepati-
tis B vaccine: ‘Medically stable preterm infants with
birth weight less than 2000 g should receive the first
dose of hepatitis B vaccine as early as 30 days of chrono-
logical age regardless of gestational age or birth’ [17].
The presented results and the review of available stud-
ies support such thesis. However, the implementation of
the AAP guidelines in other countries should be consid-
ered carefully. The local risk of HBV infection should
constitute the main factor influencing hepatitis B vacci-
nation policy. Balancing the risk of infection (current
epidemiological status of Poland) and the lack of efficacy
of early vaccination in extremely immature babies of
HBsAg negative mothers, the authors suggest that the
vaccination of newborns born before the 28th week of
gestational age should be delayed until the 2nd month of
life. Moreover, in babies with an increased risk of non-
responding to vaccination, such as a history of Gram
negative sepsis and poor weight gain, the evaluation of
antiHBs level after primary vaccination should be con-
sidered. In preterm babies before the 3rd dose of hepati-
tis B vaccination, after major surgical procedures if
antiHBs level is not known, hepatitis B immunoglobulin
(HBIG) should be administered.
CONCLUSIONS
In the studied population the response of early vacci-
nated babies was significantly lower compared to the
late vaccinated babies. Newborns’ response to hepatitis
B vaccination depends on post conceptual age. The
authors suggest that the vaccination of newborns born
before the 28th week of gestational age should be
delayed until the 2nd month of life. There is no evidence
that a 4-dose schedule is more effective than a 3-dose
schedule in preterm infants.
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